Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
India's treatment of obesity and type 2 diabetes is at a turning point with the patent expiry of semaglutide, a widely used GLP-1 receptor agonist, and the emergence of tirzepatide, a dual-hormone mechanism drug. The generic versions of semaglutide are expected to increase affordability and access, but also raise concerns about quality and safety monitoring.
India is at a turning point in treating obesity and type 2 diabetes. The patent for semaglutide, a GLP-1 receptor agonist, expired on March 20, 2026. Generic versions are expected to enter the market, increasing affordability and access. Tirzepatide, a dual-hormone mechanism drug, has shown superior diabetes and weight loss results. The development has sparked discussion among endocrinologists and pharmaceutical experts about cost, access, safety, and quality. The generic versions of semaglutide may lower costs but raise concerns about quality and safety monitoring. Tirzepatide targets both GLP-1 and GIP receptors, enhancing insulin secretion and reducing appetite. The Indian market is expected to see an aggressive wave of generic semaglutide formulations, expanding access to effective treatment options.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.